Biora Therapeutics, INC

Biora Therapeutics has commenced a Chapter 11 sale process to strengthen its balance sheet and advance product development, supported by up to $10.25 million in new financing.

Biora Therapeutics will be delisted from the Nasdaq due to non-compliance with market value requirements and will begin trading on the OTC Markets.

Biora Therapeutics has received a delisting notice from Nasdaq due to its market value of publicly held shares falling below the required threshold, despite being granted an extension to regain compliance with a separate market value rule.

Biora Therapeutics announced a strategic shift towards licensing its BioJet device, along with Q3 2024 financial results and an extension to regain Nasdaq compliance.

Biora Therapeutics has completed a registered direct offering of common stock and warrants, raising approximately $3 million in gross proceeds.

Biora Therapeutics has approved a 1-for-10 reverse stock split and a reduction in authorized shares, effective October 18, 2024.

Biora Therapeutics' Q3 2024 report reveals a net loss of $16.1 million for the nine-month period, alongside significant financial restructuring and ongoing concerns about the company's ability to continue as a going concern.

Biora Therapeutics reports a net income of $6.5 million for Q2 2024, driven by gains on warrant and derivative liabilities, while facing going concern doubts due to insufficient cash to fund operations for the next 12 months.

Biora Therapeutics reports a net loss of $4.2 million for Q1 2024 and expresses substantial doubt about its ability to continue as a going concern.

Biora Therapeutics amends its indenture related to convertible notes and files its annual report on Form 10-K for the fiscal year ended December 31, 2023.

Athyrium Opportunities funds and related entities acquired additional convertible notes in Biora Therapeutics as payment-in-kind interest, increasing their beneficial ownership.

CEO Aditya Mohanty disposed of shares of Biora Therapeutics to cover tax withholding obligations related to vested restricted stock units.

Clarke Neumann, an officer at Biora Therapeutics, disposed of 26,629 shares to cover tax obligations related to vested restricted stock units.

Eric d'Esparbes, CFO of Biora Therapeutics, reports the disposal of 27,830 shares of common stock to cover tax obligations related to vested restricted stock units.

Athyrium Opportunities III Co-Invest 1 LP and related entities have entered into a Convertible Notes Exchange Agreement with Biora Therapeutics, Inc. to restructure their holdings of convertible notes and warrants.

Athyrium Opportunities III Acquisition LP and Athyrium Opportunities III Co-Invest 1 LP receive warrants to purchase Biora Therapeutics common stock in exchange for forbearing from exercising certain rights under convertible notes.

Biora Therapeutics is holding a special meeting to seek stockholder approval for issuing shares related to convertible notes and warrants, as well as to amend its equity incentive plan.

Biora Therapeutics is asking stockholders to approve a reverse stock split and a reduction in authorized shares to regain compliance with Nasdaq listing requirements.

Biora Therapeutics is holding its annual stockholder meeting on June 5, 2024, seeking approval for director elections, auditor ratification, an increase in authorized shares, and authorization for the issuance of shares related to recent warrant agreements.

Biora Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 5, 2024, to vote on key proposals including the election of directors, ratification of the independent auditor, increasing authorized shares, and authorizing the issuance of shares underlying certain warrants.

Athyrium Group has updated its beneficial ownership in Biora Therapeutics, Inc., reporting an aggregate 49.9% stake, concurrent with the resignation of Jeffrey A. Ferrell from the company's board of directors.

Davidson Kempner Capital Management and its affiliates have disclosed a 9.90% beneficial ownership stake in Biora Therapeutics, Inc., primarily through convertible notes, subject to a 9.90% ownership blocker.

Margaret Ellen Taggett has disclosed a 6.6% passive ownership stake in Biora Therapeutics, Inc., holding 297,000 shares of common stock.

Context Capital Management, along with its affiliates, has reported a beneficial ownership of 0.5% in BIORA THERAPEUTICS, INC., totaling 22,025 shares of common stock.